RU2016147003A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016147003A3 RU2016147003A3 RU2016147003A RU2016147003A RU2016147003A3 RU 2016147003 A3 RU2016147003 A3 RU 2016147003A3 RU 2016147003 A RU2016147003 A RU 2016147003A RU 2016147003 A RU2016147003 A RU 2016147003A RU 2016147003 A3 RU2016147003 A3 RU 2016147003A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20145449 | 2014-05-19 | ||
| FI20145449 | 2014-05-19 | ||
| PCT/EP2015/060903 WO2015177098A2 (en) | 2014-05-19 | 2015-05-18 | Modified adenoviruses for cancer vaccines development |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016147003A RU2016147003A (ru) | 2018-06-20 |
| RU2016147003A3 true RU2016147003A3 (enExample) | 2018-11-08 |
| RU2695375C2 RU2695375C2 (ru) | 2019-07-23 |
Family
ID=53189815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147003A RU2695375C2 (ru) | 2014-05-19 | 2015-05-18 | Покрытые онколитические аденовирусы для противораковых вакцин |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799568B2 (enExample) |
| EP (1) | EP3145537B1 (enExample) |
| JP (3) | JP6705755B2 (enExample) |
| KR (1) | KR102437072B1 (enExample) |
| CN (2) | CN107073089A (enExample) |
| AU (2) | AU2015263286B2 (enExample) |
| CA (1) | CA2949174A1 (enExample) |
| ES (1) | ES2714921T3 (enExample) |
| NZ (1) | NZ726112A (enExample) |
| RU (1) | RU2695375C2 (enExample) |
| WO (1) | WO2015177098A2 (enExample) |
| ZA (1) | ZA201607715B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| JP6705755B2 (ja) * | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ | 癌ワクチン開発のための改変アデノウイルス |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3363447A4 (en) * | 2015-10-12 | 2019-07-03 | Industry - University Cooperation Foundation Hanyang University | ADENOVIRUS COMPLEX FOR TRANSFER AND GENE THERAPY |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EP3675902A4 (en) | 2017-08-28 | 2021-06-23 | Board of Trustees of Michigan State University | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND INFECTION USING BACTERIOPHAGE AND THEIR MUTANTS |
| US20200397892A1 (en) * | 2018-02-22 | 2020-12-24 | Turnstone Limited Partnership | Oncolytic viruses as adjuvants |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
| US20230144068A1 (en) * | 2020-03-31 | 2023-05-11 | Kaneka Corporation | Method for preparing modified vector and method for modifying vector |
| GB202006760D0 (en) | 2020-05-07 | 2020-06-24 | Univ Helsinki | Bioinformatics |
| GB202013834D0 (en) | 2020-09-03 | 2020-10-21 | Valo Therapeutics Oy | PeptiVAX therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569426B2 (en) * | 1997-04-03 | 2003-05-27 | Genzyme Corporation | Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity |
| WO1999025379A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
| EP1108047A1 (en) * | 1998-08-27 | 2001-06-20 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| KR100773109B1 (ko) * | 1999-05-06 | 2007-11-02 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| DE60142840D1 (de) * | 2000-09-08 | 2010-09-30 | Univ Texas | Durch phagendisplay identifizierte zielpeptide des menschen und der maus |
| AU2002308713B2 (en) * | 2001-06-22 | 2008-05-15 | The Trustees Of The University Of Pennsylvania | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| US20040009939A1 (en) * | 2002-03-05 | 2004-01-15 | Board Of Regent, The University Of Texas System | Methods of enhancing immune induction involving MDA-7 |
| EP1497412A4 (en) * | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS USED IN IMMUNOTHERAPY |
| US20040102382A1 (en) * | 2002-11-27 | 2004-05-27 | Transgene, S.A. | Targeting peptides |
| US7776322B2 (en) * | 2004-08-16 | 2010-08-17 | Stefan Kochanek | Modified viral vector particles |
| US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP1985708B1 (en) | 2007-04-27 | 2015-04-15 | Universität Rostock | Selective targeting of viruses to neural precursor cells |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| ES2335077B1 (es) | 2008-12-30 | 2011-02-02 | Instituto Aragones De Ciencias De La Salud | Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores. |
| WO2011017162A2 (en) * | 2009-08-03 | 2011-02-10 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
| RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20140140962A1 (en) * | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
| US20120308660A1 (en) * | 2011-06-02 | 2012-12-06 | Paxvax, Inc. | Nanocoatings for biological materials |
| JP6705755B2 (ja) * | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ | 癌ワクチン開発のための改変アデノウイルス |
-
2015
- 2015-05-18 JP JP2016568387A patent/JP6705755B2/ja active Active
- 2015-05-18 WO PCT/EP2015/060903 patent/WO2015177098A2/en not_active Ceased
- 2015-05-18 US US15/312,388 patent/US10799568B2/en active Active
- 2015-05-18 RU RU2016147003A patent/RU2695375C2/ru active
- 2015-05-18 CN CN201580026994.7A patent/CN107073089A/zh active Pending
- 2015-05-18 ES ES15723503T patent/ES2714921T3/es active Active
- 2015-05-18 NZ NZ726112A patent/NZ726112A/en unknown
- 2015-05-18 AU AU2015263286A patent/AU2015263286B2/en active Active
- 2015-05-18 CA CA2949174A patent/CA2949174A1/en active Pending
- 2015-05-18 KR KR1020167035173A patent/KR102437072B1/ko active Active
- 2015-05-18 CN CN202511457024.4A patent/CN121313807A/zh active Pending
- 2015-05-18 EP EP15723503.7A patent/EP3145537B1/en active Active
-
2016
- 2016-11-09 ZA ZA2016/07715A patent/ZA201607715B/en unknown
-
2020
- 2020-03-16 JP JP2020045322A patent/JP7030867B2/ja active Active
- 2020-05-22 JP JP2020089965A patent/JP7657028B2/ja active Active
- 2020-06-10 AU AU2020203816A patent/AU2020203816B2/en active Active
- 2020-09-02 US US17/009,929 patent/US11730798B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016147003A (ru) | 2018-06-20 |
| EP3145537A2 (en) | 2017-03-29 |
| NZ764519A (en) | 2021-08-27 |
| JP7657028B2 (ja) | 2025-04-04 |
| US11730798B2 (en) | 2023-08-22 |
| NZ726112A (en) | 2021-07-30 |
| ES2714921T3 (es) | 2019-05-30 |
| US10799568B2 (en) | 2020-10-13 |
| CA2949174A1 (en) | 2015-11-26 |
| EP3145537B1 (en) | 2018-12-12 |
| ZA201607715B (en) | 2017-09-27 |
| AU2015263286B2 (en) | 2020-03-12 |
| BR112016026745A2 (pt) | 2017-12-12 |
| WO2015177098A2 (en) | 2015-11-26 |
| US20170080069A1 (en) | 2017-03-23 |
| AU2015263286A1 (en) | 2016-11-24 |
| JP6705755B2 (ja) | 2020-06-03 |
| RU2695375C2 (ru) | 2019-07-23 |
| KR102437072B1 (ko) | 2022-08-26 |
| CN107073089A (zh) | 2017-08-18 |
| AU2020203816B2 (en) | 2021-11-18 |
| CN121313807A (zh) | 2026-01-13 |
| JP2017522267A (ja) | 2017-08-10 |
| JP7030867B2 (ja) | 2022-03-07 |
| WO2015177098A3 (en) | 2016-02-18 |
| JP2020110165A (ja) | 2020-07-27 |
| US20210100883A1 (en) | 2021-04-08 |
| JP2020143128A (ja) | 2020-09-10 |
| AU2020203816A1 (en) | 2020-07-02 |
| KR20170012326A (ko) | 2017-02-02 |